Literature DB >> 25762129

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results.

C Gianniou, A Dirani, W Ferrini, L Marchionno, D Decugis, A Deli, A Ambresin, I Mantel.   

Abstract

Year:  2015        PMID： 25762129      PMCID： PMC4366476          DOI： 10.1038/eye.2014.321

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  8 in total

1.  Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept.

Authors:  Parmis Parvin; Marta Zola; Ali Dirani; Aude Ambresin; Irmela Mantel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-10       Impact factor: 3.117

2.  Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.

Authors:  Joachim Wachtlin; Georg Spital; Steffen Schmitz-Valckenberg; Sandra Liakopoulos; Jessica Vögeler; Bettina Müller; Focke Ziemssen
Journal:  J Ophthalmol       Date:  2020-07-16       Impact factor: 1.909

3.  Patient satisfaction following a switch from treat-and-extend to observe-and-plan regimen in age-related macular degeneration.

Authors:  Tora Sund Morken; Christina Knutsen; Margrete Sætre Hanssen; Dordi Austeng
Journal:  BMJ Open Ophthalmol       Date:  2022-01-07

4.  TREATMENT DEFERRAL DURING COVID-19 LOCKDOWN: Functional and Anatomical Impact on Patients With Neovascular Age-Related Macular Degeneration.

Authors:  Andrea Montesel; Anthony Gigon; Clarice Giacuzzo; Irmela Mantel; Chiara M Eandi
Journal:  Retina       Date:  2022-04-01       Impact factor: 4.256

5.  The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.

Authors:  Jennifer J Arnold; Caroline M Markey; Nicol P Kurstjens; Robyn H Guymer
Journal:  BMC Ophthalmol       Date:  2016-03-24       Impact factor: 2.209

Review 6.  Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.

Authors:  Alfredo García-Layana; Marta S Figueroa; Javier Araiz; José M Ruiz-Moreno; Francisco Gómez-Ulla; Luis Arias-Barquet; Nicholas Reiter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

7.  MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.

Authors:  Irmela Mantel; Ali Dirani; Marta Zola; Parmis Parvin; Sophie De Massougnes; Ciara Bergin
Journal:  Retina       Date:  2019-05       Impact factor: 4.256

8.  Safety and clinical effectiveness of intravitreal administration of bevacizumab (Lumiere®) in patients with neovascular age-related macular degeneration.

Authors:  Daniel A Benisek; Julio Manzitti; Daniel Scorsetti; Andres M Rousselot Ascarza; Amalia A Ascarza; Diego Gomez Rancaño; Romina Quercia; Matias Ramirez Gismondi; Mateo A Carpio Total; María L Scorsetti; Eduardo Spitzer; Carola Lombas; Matías Deprati; María Ines Penna; Francisco Fernández; Marcelo A Tinelli
Journal:  Exp Ther Med       Date:  2020-10-09       Impact factor: 2.447
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.